BACKGROUND: Increasing drug resistance in Plasmodium falciparum has necessitated renewed search for cheap, effective alternatives to commonly available antimalarials, chloroquine and pyrimethamine-sulphadoxine, for the treatment of malaria in Africa. Probenecid, an inhibitor of organic anion transporters and multiresistance-associated proteins, can chemosensitize P. falciparum to pyrimethamine and sulphadoxine in vitro, but the clinical significance is unclear. We assessed the safety, treatment efficacy, and effects on gametocyte carriage of adding probenecid to pyrimethamine-sulphadoxine. METHODS: We evaluated 151 children aged 12 years or younger who had uncomplicated P. falciparum malaria. Patients were randomly assigned pyrimethamine-sulphadoxine (25 mg/kg of the sulphadoxine component) or pyrimethamine-sulphadoxine as above plus probenecid 20-25 mg/kg of bodyweight in two divided doses daily for 3 days. The primary endpoints were parasitological cure rates on days 14 and 28. RESULTS: Both regimens were well tolerated; no child was withdrawn because of drug intolerance. Fever (1.9 +/- 1.1 vs. 2.4 +/- 1.2 days, P = 0.02) and parasite clearance (2.3 +/- 0.9 vs. 2.7 +/- 1.1 days, P = 0.04) were significantly shorter, and the parasitological cure rate on day 14 (96.2%vs. 83.5%, P = 0.02) but not day 28 (79.4%vs. 72.6%, P = 0.4), was significantly higher in children treated with pyrimethamine-sulphadoxine-probenecid than in those treated with pyrimethamine-sulphadoxine. Gametocyte carriage was similar with both treatment regimens. CONCLUSIONS: The combination of pyrimethamine-sulphadoxine, and probenecid, at a relatively moderate dose, improved treatment efficacy but had no effect on gametocyte carriage. The pyrimethamine-sulphadoxine-probenecid combination merits further evaluation as a potential treatment for use in Nigeria.
RCT Entities:
BACKGROUND: Increasing drug resistance in Plasmodium falciparum has necessitated renewed search for cheap, effective alternatives to commonly available antimalarials, chloroquine and pyrimethamine-sulphadoxine, for the treatment of malaria in Africa. Probenecid, an inhibitor of organic anion transporters and multiresistance-associated proteins, can chemosensitize P. falciparum to pyrimethamine and sulphadoxine in vitro, but the clinical significance is unclear. We assessed the safety, treatment efficacy, and effects on gametocyte carriage of adding probenecid to pyrimethamine-sulphadoxine. METHODS: We evaluated 151 children aged 12 years or younger who had uncomplicated P. falciparum malaria. Patients were randomly assigned pyrimethamine-sulphadoxine (25 mg/kg of the sulphadoxine component) or pyrimethamine-sulphadoxine as above plus probenecid 20-25 mg/kg of bodyweight in two divided doses daily for 3 days. The primary endpoints were parasitological cure rates on days 14 and 28. RESULTS: Both regimens were well tolerated; no child was withdrawn because of drug intolerance. Fever (1.9 +/- 1.1 vs. 2.4 +/- 1.2 days, P = 0.02) and parasite clearance (2.3 +/- 0.9 vs. 2.7 +/- 1.1 days, P = 0.04) were significantly shorter, and the parasitological cure rate on day 14 (96.2%vs. 83.5%, P = 0.02) but not day 28 (79.4%vs. 72.6%, P = 0.4), was significantly higher in children treated with pyrimethamine-sulphadoxine-probenecid than in those treated with pyrimethamine-sulphadoxine. Gametocyte carriage was similar with both treatment regimens. CONCLUSIONS: The combination of pyrimethamine-sulphadoxine, and probenecid, at a relatively moderate dose, improved treatment efficacy but had no effect on gametocyte carriage. The pyrimethamine-sulphadoxine-probenecid combination merits further evaluation as a potential treatment for use in Nigeria.
Authors: Ahmed A Adedeji; Bilqees Sanusi; Azeez Tella; Motunrayo Akinsanya; Olubusola Ojo; Mufliat O Akinwunmi; Olubukola A Tikare; Isiaka A Ogunwande; Omobola A Ogundahunsi; Olajide O Ayilara; Taofeeqah T Ademola; Fatai A Fehintola; Olumide A T Ogundahunsi Journal: Malar J Date: 2011-08-09 Impact factor: 2.979
Authors: J Enrique Salcedo-Sora; Edwin Ochong; Susan Beveridge; David Johnson; Alexis Nzila; Giancarlo A Biagini; Paul A Stocks; Paul M O'Neill; Sanjeev Krishna; Patrick G Bray; Stephen A Ward Journal: J Biol Chem Date: 2011-10-13 Impact factor: 5.157
Authors: Grace O Gbotosho; Christian T Happi; Abideen Ganiyu; Olumide A Ogundahunsi; Akin Sowunmi; Ayoade M Oduola Journal: Malar J Date: 2009-12-30 Impact factor: 2.979
Authors: Jack Rubinstein; Jessica G Woo; Anastacia M Garcia; Tarek Alsaied; Jia Li; Per Kristian Lunde; Ryan A Moore; Martin Laasmaa; Amanda Sammons; Wayne A Mays; Shelley D Miyamoto; William E Louch; Gruschen R Veldtman Journal: Pediatr Cardiol Date: 2020-08-07 Impact factor: 1.655
Authors: Nathan Robbins; Mark Gilbert; Mohit Kumar; James W McNamara; Patrick Daly; Sheryl E Koch; Ginger Conway; Mohamed Effat; Jessica G Woo; Sakthivel Sadayappan; Jack Rubinstein Journal: J Am Heart Assoc Date: 2018-01-13 Impact factor: 5.501